Lois Groden

Vice President, Europe

Lois has 4 years’ M&A and corporate finance experience, having joined CG Results in 2017 as an Analyst in the Healthcare team. She is currently an Associate and has advised a range of clients including private equity firms, large pharmaceutical companies and high growth, founder owned businesses, spanning the entire life sciences and broader healthcare sector.

Prior to CG Results, Lois graduated with a distinction in her MSc in Biotechnology, Bioprocessing and Business Management from the University of Warwick and also holds a BSc in Genetics from the University of York. Lois previously spent time in Italy teaching English to children.

Outside of work, Lois is an avid attender of exercise classes (namely Barry’s Bootcamp) and is a keen short distance runner, balanced by spending time socialising with friends. She also enjoys reading, skiing, and exploring new cultures through travel.

Latest Insights

23rd February 2022

CRO Sector – M&A drivers and market trends – Q1 2022

Whilst the pandemic has caused unprecedented disruption on research and clinical trials, it has also launched the clinical trial landscape into a new area, one with the enhanced utilisation of decentralised trials and the long-awaited embracement of digital technologies to deliver improved patient care, reduced clinical trial costs and speedier outcomes. We have also seen […]

18th March 2021

CRO Sector Update: March 2021

M&A and valuations in the CRO sector – March 2021 The level of impact that Covid-19 has had on M&A activity is comparable to that of the Great Financial Crisis, however, the rebound has been notably stronger. In the last year c.70 deals completed with a significant contribution from the second half of the year. […]

15th June 2020

CRO Sector Update: June 2020

The impact of COVID-19 on M&A and valuations in the CRO sectorUnsurprisingly, the CRO market, like many other sectors has been impacted markedly by the global pandemic. Global trials have been suspended as patient recruitment has become strained and operating sites closed. Pharma sponsors have begun to rethink how to adapt the drug development paradigm […]